EIF4E1B and central nervous system cancer: APOBEC3F (HR: 0.395, 95%CI: 0.201–0.778, p = 0.007) and EIF4E1B (HR: 0.568 95%CI: 0.342–0.943, p = 0.029) were positively associated with clinical outcomes in glioma patients.